At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
Ofatumumab +1 moredrug
Likely dose
Ofatumumab 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Ofatumumab for Lymphoma, Follicular. Completed, enrolled 116 participants across 1 site.
Detailed Summary
A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Follicular
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartMay 2007
Primary CompletionApr 2009
Study CompletionSep 2013
TodayJul 2026
First PostedNov 1, 2006
Enrollment StartMay 1, 2007
Primary CompletionApr 1, 2009
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.7 years ago
Interventions
Ofatumumabdrug
Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
Ofatumumabdrug
followed by 7 weekly infusions of 1000mg ofatumumab